Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BRII-179,VIR-2218
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Brii Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VBI-2601 (BRII-179) is a novel recombinant, protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI’s prophylactic 3-antigen HBV vaccine candidate and is designed to target enhanced B-cell and T-cell immunity.
Brand Name : VBI-2601
Molecule Type : Vaccine
Upfront Cash : Not Applicable
September 06, 2023
Lead Product(s) : BRII-179,VIR-2218
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Brii Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VIR-2218,VIR-3434
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Alnylam Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Combinations of VIR-3434, VIR-2218, pegylated interferon alpha (PEG-IFNα) and a nucleoside reverse transcriptase inhibitor (NRTI) are being investigated in hepatitis B virus (HBV) immune-active, treatment-naïve adults.
Brand Name : VIR-2218
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 11, 2023
Lead Product(s) : VIR-2218,VIR-3434
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Alnylam Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BRII-179,VIR-2218
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VBI-2601 (BRII-179) is a novel recombinant, protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI’s prophylactic 3-antigen HBV vaccine candidate and is designed to target enhanced B-cell and T-cell immunity.
Brand Name : VBI-2601
Molecule Type : Vaccine
Upfront Cash : Not Applicable
February 15, 2023
Lead Product(s) : BRII-179,VIR-2218
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VIR-2218,VIR-3434
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Preliminary data to-date show that 30.8% of participants receiving 48 weeks of VIR-2218 plus pegylated interferon alpha achieved HBsAg seroclearance with anti-HBs seroconversion by end of treatment.
Brand Name : VIR-2218
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 06, 2022
Lead Product(s) : VIR-2218,VIR-3434
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VIR-2218,VIR-3434
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
Details : Results from ongoing trials of VIR-2218 and VIR-3434 presented at demonstrated durable reductions in hepatitis B surface antigen with no safety signals.
Brand Name : VIR-2218
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 25, 2022
Lead Product(s) : VIR-2218,VIR-3434
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VIR-2218,VIR-3434
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The oral presentation will highlight new dose and duration data from a Phase 2 trial evaluating VIR-2218, an investigational HBV-targeting small interfering ribonucleic acid that mediates RNA interference, for potential functional cure of chronic HBV inf...
Brand Name : VIR-2218
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 08, 2022
Lead Product(s) : VIR-2218,VIR-3434
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VIR-2218,VIR-3434
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BRII-835 (VIR-2218) is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV.
Brand Name : BRII-835
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 27, 2022
Lead Product(s) : VIR-2218,VIR-3434
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VIR-2218,BRII-179
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The data demonstrate that BRII-835 (VIR-2218), an small interfering ribonucleic acid that mediates RNA interference, results in dose-dependent reduction in hepatitis B surface antigen in Chinese patients with chronic HBV infection who received two doses ...
Brand Name : VIR-2218
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 31, 2022
Lead Product(s) : VIR-2218,BRII-179
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VIR-3434,VIR-2218
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Preliminary results from an ongoing Phase 2 clinical trial of VIR-2218, alone or in combination with other therapies, and an ongoing Phase 1 clinical trial of VIR-3434, continue to demonstrate notable reductions in hepatitis B surface antigen and positiv...
Brand Name : VIR-3434
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 12, 2021
Lead Product(s) : VIR-3434,VIR-2218
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VIR-3434,VIR-2218
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VIR-2218 is an investigational small interfering ribonucleic acid (siRNA) designed to inhibit the production of all HBV proteins (X, polymerase, S and core), which may be acting as immune tolerogens.
Brand Name : VIR-3434
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 15, 2021
Lead Product(s) : VIR-3434,VIR-2218
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?